Exhibit 1.1
EXECUTION COPY
5,000,000 Shares
ImmunoGen, Inc.
Common Stock
UNDERWRITING
AGREEMENT
June 18, 2009
Oppenheimer & Co. Inc.
as Representative of the
several
Underwriters named in Schedule
I hereto
300 Madison Avenue
New York, New York 10017
Ladies and Gentlemen:
ImmunoGen, Inc., a
Massachusetts corporation (the “Company”), proposes,
subject to the terms and conditions contained herein, to sell to
you, Oppenheimer & Co. Inc., and the other underwriters
named on Schedule I to this Agreement (the
“Underwriters”), for whom you are acting as
Representative (the “Representative”), an aggregate of
5,000,000 shares (the “Firm Shares”) of the
Company’s common stock, $.01 par value per share (the
“Common Stock”). In addition, the Company
proposes to grant to the Underwriters an option to purchase up to
an additional 750,000 shares (the “Company Option
Shares”) of Common Stock from the Company for the purpose of
covering over-allotments in connection with the sale of the Firm
Shares. The Firm Shares and the Option Shares are
collectively called the “Shares.”
The Company has prepared and filed
in conformity with the requirements of the Securities Act of 1933,
as amended (the “Securities Act”), and the published
rules and regulations thereunder (the “Rules”)
adopted by the Securities and Exchange Commission (the
“Commission”) a registration statement on Form S-3
(No. 333-144488), including a related prospectus dated
August 13, 2007 (the “Base Prospectus”) relating
to Common Stock that may be sold from time to time by the Company
in accordance with Rule 415 of the Securities Act, and such
amendments thereof as may have been required to the date of this
Agreement. Copies of such Registration Statement (including all
amendments thereof and all documents deemed incorporated by
reference therein) and of the related Base Prospectus have
heretofore been delivered by the Company or are otherwise available
to you.
The term “Registration
Statement” as used in this Agreement means the registration
statement, including all exhibits, financial schedules and all
documents and information deemed to be part of the Registration
Statement by incorporation by reference or otherwise, as amended
from time to time, including the information (if any) contained in
the form of final prospectus filed with the Commission pursuant to
Rule 424(b) of the Rules and deemed to be part
thereof at the time of effectiveness pursuant to Rule 430A of
the Rules.
If the Company has filed an
abbreviated registration statement to register additional Shares
pursuant to Rule 462(b) under the Rules (the
“462(b) Registration Statement”), then any
reference herein to the Registration Statement shall also be deemed
to include such 462(b) Registration Statement. The term
“Preliminary Prospectus” means the Base Prospectus, any
preliminary prospectus supplement used or filed with the Commission
pursuant to Rule 424 of the Rules, in the form provided to the
Underwriters by the Company for use in connection with the offering
of the Shares. The term “Prospectus” means the
Base Prospectus, any Preliminary Prospectus and any amendments or
further supplements to such prospectus, and including, without
limitation, the final prospectus supplement, filed pursuant to and
within the limits described in Rule 424(b) with the
Commission in connection with the proposed sale of the Shares
contemplated by this Agreement through the date of such prospectus
supplement. The term “Effective Date” shall mean each
date that the Registration Statement and any post-effective
amendment or amendments thereto became or become effective. Unless
otherwise stated herein, any reference herein to the Registration
Statement, any Preliminary Prospectus, the Statutory Prospectus (as
hereinafter defined) and the Prospectus shall be deemed to refer to
and include the documents incorporated by reference therein,
including pursuant to Item 12 of Form S-3 under the Securities
Act, which were filed under the Securities Exchange Act of 1934, as
amended (the “Exchange Act”) on or before the date
hereof or are so filed hereafter. Any reference herein to the terms
“amend,” “amendment” or
“supplement” with respect to the Registration
Statement, any Preliminary Prospectus, the Statutory Prospectus or
the Prospectus shall be deemed to refer to and include any such
document filed or to be filed under the Exchange Act after the date
of the Registration Statement, any such Preliminary Prospectus, the
Statutory Prospectus or Prospectus, as the case may be, and deemed
to be incorporated therein by reference.
The Company understands that the
Underwriters propose to make a public offering of the Shares, as
set forth in and pursuant to the Statutory Prospectus and the
Prospectus, as soon after the Effective Date and the date of this
Agreement as the Representative deems advisable. The Company
hereby confirms that the Underwriters and dealers have been
authorized to distribute or cause to be distributed each
Preliminary Prospectus, and each Issuer Free Writing Prospectus (as
hereinafter defined) and are authorized to distribute the
Prospectus (as from time to time amended or supplemented if the
Company furnishes amendments or supplements thereto to the
Underwriters).
1.
Sale, Purchase, Delivery and
Payment for the Shares . On the basis of the representations,
warranties and agreements contained in, and subject to the terms
and conditions of, this Agreement:
(a)
The Company agrees to issue and sell
to each of the Underwriters, and each of the Underwriters agrees,
severally and not jointly, to purchase from the Company, at a
purchase
2
price of $7.00 per share (the “Initial
Price”), the number of Firm Shares set forth opposite the
name of such Underwriter under the column “Number of Firm
Shares to be Purchased” on Schedule I to this
Agreement, subject to adjustment in accordance with Section 9
hereof.
(b)
The Company hereby grants to the
several Underwriters an option to purchase, severally and not
jointly, all or any part of the Option Shares at the Initial Price.
The number of Option Shares to be purchased by each
Underwriter shall be the same percentage (adjusted by the
Representative to eliminate fractions) of the total number of
Option Shares to be purchased by the Underwriters as such
Underwriter is purchasing of the Firm Shares. Such option may
be exercised only to cover over-allotments in the sales of the Firm
Shares by the Underwriters and may be exercised in whole or in part
(but not more than once) at any time on or before 12:00 noon, New
York City time, on the business day before the Firm Shares Closing
Date (as defined below), and from time to time thereafter within 30
days after the date of this Agreement, in each case upon written,
facsimile or telegraphic notice, or verbal or telephonic notice
confirmed by written, facsimile or telegraphic notice, by the
Representative to the Company no later than 12:00 noon, New York
City time, on the business day before the Firm Shares Closing Date
or at least two business days before the Option Shares Closing Date
(as defined below), as the case may be, setting forth the number of
Option Shares to be purchased and the time and date (if other than
the Firm Shares Closing Date) of such purchase.
(c)
Payment of the purchase price for,
and delivery of certificates for, the Firm Shares shall be made at
the offices of Oppenheimer & Co. Inc., 300 Madison Avenue,
New York, New York 10017, at 10:00 a.m., New York City time,
on the third business day following the date of this Agreement or
at such time on such other date, not later than ten
(10) business days after the date of this Agreement, as shall
be agreed upon by the Company and the Representative (such time and
date of delivery and payment are called the “Firm Shares
Closing Date”). In addition, in the event that any or
all of the Option Shares are purchased by the Representative,
payment of the purchase price, and delivery of the certificates,
for such Option Shares shall be made at the above-mentioned
offices, or at such other place as shall be agreed upon by the
Representative and the Company, on each date of delivery as
specified in the notice from the Representative to the Company
(such time and date of delivery and payment are called the
“Option Shares Closing Date”). The Firm Shares
Closing Date and any Option Shares Closing Date are called,
individually, a “Closing Date” and, together, the
“Closing Dates.”
(d)
Payment shall be made to the Company
by wire transfer of immediately available funds or by certified or
official bank check or checks payable in New York Clearing House
(same day) funds drawn to the order of the Company, against
delivery of the certificates to the to the Representative for the
respective accounts of the Underwriters for the Shares to be
purchased by them.
(e)
Certificates evidencing the Shares
shall be registered in such names and shall be in such
denominations as the Representative shall request at least two full
business days before the Firm Shares Closing Date or, in the case
of Option Shares, on the day of notice of exercise of the option as
described in Section 1(b) and shall be delivered by or on
behalf of the Company to the Representative through the facilities
of the Depository Trust Company (“DTC”) for the account
of the Underwriters. The Company will cause the certificates
representing the Shares to be made available for checking and
packaging, at such place as is designated by the
3
Representative, on the full business day before
the Firm Shares Closing Date (or the Option Shares Closing Date in
the case of the Option Shares).
2.
Representations and Warranties of
the Company . The
Company represents and warrants to each Underwriter as of the date
hereof, as of the Firm Shares Closing Date and as of each Option
Shares Closing Date (if any), as follows:
(a)
The Company meets the requirements
for use of Form S-3 under the Securities Act including the
transaction requirements set forth in General Instruction 1.B.1 of
such form. The Company filed with the Commission the Registration
Statement on such Form, including a Base Prospectus, for
registration under the Securities Act of the offering and sale of
the Shares, and the Company has prepared and used a Preliminary
Prospectus in connection with the offer and sale of the
Shares. When the Registration Statement or any amendment
thereof or supplement thereto was or is declared effective and as
of the date of the most recent amendment to the Registration
Statement, it (i) complied or will comply, in all material
respects, with the requirements of the Securities Act and the
Rules and the Exchange Act and the rules and regulations
of the Commission thereunder and (ii) did not or will not,
contain any untrue statement of a material fact or omit to state
any material fact required to be stated therein or necessary in
order to make the statements therein not misleading. When any
Preliminary Prospectus or Prospectus was first filed with the
Commission (whether filed as part of the Registration Statement or
any amendment thereto or pursuant to Rule 424 of the Rules)
and when any amendment thereof or supplement thereto was first
filed with the Commission, such Preliminary Prospectus or
Prospectus as amended or supplemented complied in all material
respects with the applicable provisions of the Securities Act and
the Rules and did not as of the date thereof, does not,
together with the Pricing Information (as defined below), as of the
date hereof, and will not, together with the Pricing Information,
as of the Closing Date, contain any untrue statement of a material
fact or omit to state any material fact required to be stated
therein or necessary in order to make the statements therein, in
light of the circumstances under which they were made, not
misleading. If applicable, each Preliminary Prospectus and the
Prospectus delivered to the Underwriters for use in connection with
this offering was identical to the electronically transmitted
copies thereof filed with the Commission pursuant to EDGAR, except
to the extent permitted by Regulation S-T. Notwithstanding the
foregoing, none of the representations and warranties in this
paragraph 2(a) shall apply to statements in, or omissions
from, the Registration Statement, any Preliminary Prospectus or the
Prospectus made in reliance upon, and in conformity with,
information herein or otherwise furnished in writing by the
Underwriters specifically for use in the Registration Statement,
any Preliminary Prospectus or the Prospectus. With respect to the
preceding sentence, the Company acknowledges that the only
information furnished in writing by the Underwriters for use in the
Registration Statement, any Preliminary Prospectus or the
Prospectus is the statements contained in the first sentence of the
first paragraph, the fourth and fifth sentences of the fourth
paragraph, the tenth paragraph and the thirteenth paragraph under
the caption “Underwriting” in the Prospectus
(collectively, the “Underwriting
Information”).
(b)
As of the Applicable Time (as
hereinafter defined), neither (i) the Statutory Prospectus (as
hereinafter defined) together with the Pricing Information
(collectively, the “General Disclosure Package”), nor
(ii) any individual Issuer Free Writing Prospectus when
considered together with the General Disclosure Package, included
any untrue statement of a
4
material fact or omitted to state any material
fact required to be stated therein or necessary in order to make
the statements therein, in the light of the circumstances under
which they were made, not misleading; provided, however ,
that this representation and warranty shall not apply to statements
in or omissions in the General Disclosure Package made in reliance
upon and in conformity with the Underwriter Information.
Each Issuer Free Writing Prospectus,
including any electronic road show (including without limitation
any “bona fide electronic road show” as defined in
Rule 433(h)(5) under the Securities Act) (each, a
“Road Show”) (i) is identified in Schedule
III hereto and (ii) complied when issued, and complies, in
all material respects with the requirements of the Securities Act
and the Rules and the Exchange Act and the rules and
regulations of the Commission thereunder.
As used in this Section and
elsewhere in this Agreement:
“Applicable Time” means
8:45 am (Eastern time) on the date of this Underwriting
Agreement.
“Statutory Prospectus”
as of any time means the Preliminary Prospectus relating to the
Shares immediately prior to the Applicable Time, including any
document incorporated by reference therein.
“Issuer Free Writing
Prospectus” means each “free writing prospectus”
(as defined in Rule 405 of the Rules) prepared by or on behalf
of the Company or used or referred to by the Company in connection
with the offering of the Shares, including, without limitation,
each Road Show.
“Pricing Information”
means the information set forth in Schedule IV
hereto.
(c)
The Registration Statement is
effective under the Securities Act and no stop order preventing or
suspending the effectiveness of the Registration Statement or
suspending or preventing the use of any Preliminary Prospectus, the
Prospectus or any “free writing prospectus”, as defined
in Rule 405 under the Rules, has been issued by the Commission
and, to the knowledge of the Company, no proceedings for that
purpose have been instituted or are threatened under the Securities
Act. Any required filing of any Preliminary Prospectus and/or the
Prospectus and any supplement thereto pursuant to
Rule 424(b) of the Rules has been or will be made in
the manner and within the time period required by such
Rule 424(b). Any material required to be filed by the
Company pursuant to Rule 433(d) of the Rules has
been or will be made in the manner and within the time period
required by such Rules.
(d)
The documents incorporated by
reference in the Registration Statement, any Preliminary Prospectus
and the Prospectus, at the time they became effective or were filed
with the Commission, as the case may be, complied in all material
respects with the requirements of the Securities Act and the
Rules or the Exchange Act and the rules and regulations
of the Commission thereunder, as applicable, and none of such
documents contained an untrue statement of a material fact or
omitted to state a material fact required to be stated therein or
necessary in order to make the statements therein, in the light of
the circumstances under which
5
they were made, not misleading, and any further
documents so filed and incorporated by reference in the
Registration Statement, any Preliminary Prospectus and the
Prospectus, when such documents become effective or are filed with
the Commission, as the case may be, will conform in all material
respects to the requirements of the Securities Act and the
Rules or the Exchange Act and the rules and regulations
of the Commission thereunder, as applicable, and will not contain
an untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances under which they
are made, not misleading.
(e)
Each Issuer Free Writing Prospectus,
if any, as of its issue date and at all subsequent times through
the completion of the public offer and sale of the Shares or until
any earlier date that the Company notified or notifies the
Representative as described in the next sentence, did not, does not
and will not include any information that conflicted, conflicts or
will conflict with the information contained in the Registration
Statement, including any document incorporated by reference
therein and any prospectus supplement deemed to be a part thereof
that has not been superseded or modified, the Statutory Prospectus
or the Prospectus.
If at any time following issuance of
an Issuer Free Writing Prospectus there occurred or occurs an event
or development as a result of which such Issuer Free Writing
Prospectus conflicted or would conflict with the information
contained in the Registration Statement, the Statutory Prospectus
or the Prospectus or included or would include an untrue statement
of a material fact or omitted or would omit to state a material
fact required to be stated therein or necessary in order to make
the statements therein, in the light of the circumstances
prevailing at the subsequent time, not misleading, the Company has
promptly notified or will promptly notify the Representative and
has promptly amended or will promptly amend or supplement, at its
own expense, such Issuer Free Writing Prospectus to eliminate or
correct such conflict, untrue statement or omission.
(f)
The financial statements of the
Company (including all notes and schedules thereto) included in the
Registration Statement, the Statutory Prospectus and Prospectus
present fairly in all material respects the financial position of
the Company and its consolidated subsidiaries at the dates
indicated and the statement of operations, stockholders’
equity and cash flows of the Company and its consolidated
subsidiaries for the periods specified; and such financial
statements and related schedules and notes thereto, and the
unaudited financial information filed with the Commission as part
of the Registration Statement, have been prepared in conformity
with generally accepted accounting principles, consistently applied
throughout the periods involved, except as may be otherwise
specified therein or to the extent unaudited financial statements
exclude footnotes or may by condensed or summary statements; and it
being understood that the unaudited financial statements are
subject to normal year-end adjustments.
(g)
Ernst & Young LLP (the
“Auditor”) whose reports are filed with the Commission
as a part of the Registration Statement, are and, during the
periods covered by their reports, were independent public
accountants as required by the Securities Act and the
Rules.
(h)
The Company and each of its
subsidiaries, including each entity (corporation, partnership,
joint venture, association or other business organization)
controlled directly or indirectly by the Company (each, a
“subsidiary”), is duly organized, validly existing and
in good
6
standing under the laws of their respective
jurisdictions of incorporation or organization and each such entity
has all requisite power and authority to carry on its business as
is currently being conducted as described in the Statutory
Prospectus and the Prospectus, and to own, lease and operate its
properties. The Company and each of its subsidiaries is duly
qualified to do business and is in good standing as a foreign
corporation in each jurisdiction in which the nature of the
business conducted by it or location of the assets or properties
owned, leased or licensed by it requires such qualification, except
for such jurisdictions where the failure to so qualify individually
or in the aggregate would not have a material adverse effect on the
assets, properties, condition, financial or otherwise, or in the
results of operations, business affairs or business prospects of
the Company and its subsidiaries considered as a whole (a
“Material Adverse Effect”); and to the Company’s
knowledge, no proceeding has been instituted in any such
jurisdiction revoking, limiting or curtailing, or seeking to
revoke, limit or curtail, such power and authority or
qualification. The Company has no subsidiary other than its
two wholly owned subsidiaries, ImmunoGen Securities Corp. and
ImmunoGen Europe Limited, and does not control, directly or
indirectly, any other corporation, partnership, joint venture,
association or other business organization.
(i)
The Registration Statement initially
became effective on August 13, 2007. If, immediately
prior to the third anniversary of the initial effective date of the
Registration Statement, any of the Shares remain unsold by the
Underwriters, the Company will, prior to that third anniversary
file, if it has not already done so, a new shelf registration
statement relating to the Shares, in a form satisfactory to the
Representative, will use its best efforts to cause such
registration statement to be declared effective within 180 days
after that third anniversary, and will take all other action
necessary or appropriate to permit the public offering and sale of
the Shares to continue as contemplated in the expired Registration
Statement. References herein to the “Registration
Statement” shall include such new shelf registration
statement.
(j)
The Company and each of its
subsidiaries has all requisite corporate power and authority, and
all necessary authorizations, approvals, consents, orders,
licenses, certificates and permits of and from all governmental or
regulatory bodies or any other person or entity (collectively, the
“Permits”), to own, lease and license its assets and
properties and conduct its business, all of which are valid and in
full force and effect, except where the lack of such Permits,
individually or in the aggregate, would not have a Material Adverse
Effect. The Company and each of its subsidiaries has fulfilled and
performed in all material respects all of its obligations with
respect to such Permits and no event has occurred that allows, or
after notice or lapse of time would allow, revocation or
termination thereof or results in any other material impairment of
the rights of the Company or such subsidiary thereunder.
Except as may be required under the Securities Act and state and
foreign Blue Sky laws, no other Permits are required to enter into,
deliver and perform this Agreement and to issue and sell the
Shares.
(k)
(i) At the earliest time after
the filing of the Registration Statement that the Company or
another offering participant made a bona fide offer (within
the meaning of Rule 164(h)(2) of the Rules) of the Shares
and (ii) at the date hereof , the Company was
not and is not an “ineligible issuer,” as defined in
Rule 405 of the Rules, including (but not limited to) the
Company or any other subsidiary in the preceding three years not
having been convicted of a felony or misdemeanor or having been
made the subject of a judicial or administrative decree or order as
described in Rule 405 of the Rules.
7
(l)
The Company and each of its
subsidiaries owns or possesses legally enforceable rights
(including license rights) to use all patents, patent rights,
inventions, trademarks, trademark applications, trade names,
service marks, copyrights, copyright applications, licenses,
know-how and other similar rights and proprietary knowledge
(collectively, “Intangibles”) necessary for the conduct
of its business. Neither the Company nor any of its
subsidiaries has received any written notice of, or is aware of,
any infringement of or conflict with asserted rights of others with
respect to any Intangibles, except that would not reasonably be
expected to have a Material Adverse Effect.
(m)
The Company and each of its
subsidiaries has good and marketable title in fee simple to all
real property owned by it, and good and marketable title to all
other property owned by it, in each case free and clear of all
liens, encumbrances, claims, security interests and defects, except
such as do not materially affect the value of such property and do
not materially interfere with the use made of such property by the
Company and its subsidiaries. All property held under lease
by the Company and its subsidiaries is held by them under valid,
existing and enforceable leases, free and clear of all liens,
encumbrances, claims, security interests and defects, except such
as are not material and do not materially interfere with the use
made of such property by the Company and its subsidiaries.
Subsequent to the respective dates as of which information is given
in the Registration Statement and the Prospectus, (i) there
has not been any event which could have a Material Adverse Effect;
(ii) neither the Company nor any of its subsidiaries has
sustained any loss or interference with its assets, businesses or
properties (whether owned or leased) from fire, explosion,
earthquake, flood or other calamity, whether or not covered by
insurance, or from any labor dispute or any court or legislative or
other governmental action, order or decree which would have a
Material Adverse Effect; and (iii) since the date of the
latest balance sheet included in the Registration Statement and the
Prospectus, except as disclosed therein, neither the Company nor
its subsidiaries has (A) issued any securities (other than
securities pursuant to the Company’s equity incentive plans)
or incurred any liability or obligation, direct or contingent, for
borrowed money, except such liabilities or obligations incurred in
the ordinary course of business, (B) entered into any
transaction not in the ordinary course of business or
(C) declared or paid any dividend or made any distribution on
any shares of its stock or redeemed, purchased or otherwise
acquired or agreed to redeem, purchase or otherwise acquire any
shares of its capital stock.
(n)
There is no document, contract or
other agreement required to be described in the Registration
Statement, the Statutory Prospectus or the Prospectus or to be
filed as an exhibit to the Registration Statement which is not
described or filed as required by the Securities Act or
Rules. Each description of a contract, document or other
agreement in the Registration Statement, the Statutory Prospectus
or the Prospectus accurately reflects in all respects the material
terms of the underlying contract, document or other
agreement. Each contract, document or other agreement
described in the Registration Statement, the Statutory Prospectus
or the Prospectus or listed in the exhibits to the Registration
Statement or incorporated by reference is in full force and effect
and is valid and enforceable by and against the Company or its
subsidiary, as the case may be, in accordance with its terms,
except as the enforceability thereof may be limited by bankruptcy,
insolvency, reorganization, moratorium or similar laws affecting
the enforcement of creditors’ rights generally and by general
equitable principles. Neither the Company nor any of its
subsidiaries, if a subsidiary is a party, nor to the
Company’s knowledge, any other party is in default in the
observance or performance of any term or
8
obligation to be performed by it under any such
agreement, and no event has occurred which with notice or lapse of
time or both would constitute such a default, in any such case
which default or event, individually or in the aggregate, would
have a Material Adverse Effect. No default exists, and no
event has occurred which with notice or lapse of time or both would
constitute a default, in the due performance and observance of any
term, covenant or condition, by the Company or its subsidiary, if a
subsidiary is a party thereto, of any other agreement or instrument
to which the Company or any of its subsidiaries is a party or by
which Company or its properties or business or a subsidiary or its
properties or business may be bound or affected which default or
event, individually or in the aggregate, would have a Material
Adverse Effect.
(o)
The statistical and market related
data included in the Registration Statement, the Statutory
Prospectus or the Prospectus are based on or derived from sources
that the Company believes to be reliable and accurate.
(p)
Neither the
Company nor any subsidiary (i) is in violation of its
certificate or articles of incorporation or organization, by-laws,
certificate of formation, limited liability company agreement,
partnership agreement or other organizational documents,
(ii) is in default under, and no event has occurred which,
with notice or lapse of time, or both, would constitute a default
under, or result in the creation or imposition of any lien, charge,
mortgage, pledge, security interest, claim, limitation on voting
rights, equity, trust or other encumbrance, preferential
arrangement, defect or restriction of any kind whatsoever, upon,
any property or assets of the Company or any subsidiary pursuant
to, any bond, debenture, note, indenture, mortgage, deed of trust,
loan agreement or other agreement or instrument to which it is a
party or by which it is bound or to which any of its properties or
assets is subject or (iii) is in violation of any statute,
law, rule, regulation, ordinance, directive, judgment, decree or
order of any judicial, regulatory or other legal or governmental
agency or body, foreign or domestic, except (in the case of clauses
(ii) and (iii) above) for violations or defaults that
could not (individually or in the aggregate) reasonably be expected
to have a Material Adverse Effect.
(q)
This Agreement has been duly
authorized, executed and delivered by the Company.
(r)
Neither the execution, delivery and
performance of this Agreement by the Company nor the consummation
of any of the transactions contemplated hereby (including, without
limitation, the issuance and sale by the Company of the Shares)
will give rise to a right to terminate or accelerate the due date
of any payment due under, or conflict with or result in the breach
of any term or provision of, or constitute a default (or an event
which with notice or lapse of time or both would constitute a
default) under, or require any consent or waiver under, or result
in the execution or imposition of any lien, charge or encumbrance
upon any properties or assets of the Company or its subsidiaries
pursuant to the terms of, any indenture, mortgage, deed of trust or
other agreement or instrument to which the Company or any of its
subsidiaries is a party or by which either the Company or its
subsidiaries or any of their properties or businesses is bound, or
any franchise, license, permit, judgment, decree, order, statute,
rule or regulation applicable to the Company or any of its
subsidiaries or violate any provision of the charter or by-laws of
the Company or any of its subsidiaries, except for such consents or
waivers which have already been obtained and are in full force and
effect.
9
(s)
The Company has authorized and
outstanding capital stock as of March 31, 2009 as set forth in
the Statutory Prospectus and the Prospectus. The certificates
evidencing the Shares are in due and proper legal form and have
been duly authorized for issuance by the Company. All of the
issued and outstanding shares of Common Stock have been duly and
validly issued and are fully paid and nonassessable. There
are no statutory preemptive or other similar rights to subscribe
for or to purchase or acquire any shares of Common Stock of the
Company or any of its subsidiaries or any such rights pursuant to
its certificate or articles of incorporation or organization or
by-laws or any agreement or instrument to or by which the Company
or any of its subsidiaries is a party or bound. The Shares,
when issued and sold pursuant to this Agreement, will be duly and
validly issued, fully paid and nonassessable and none of them will
be issued in violation of any preemptive or other similar
right. Except as disclosed in the Registration Statement, the
Statutory Prospectus and the Prospectus, there is no outstanding
option, warrant or other right calling for the issuance of, and
there is no commitment, plan or arrangement to issue, any share of
stock of the Company or any of its subsidiaries or any security
convertible into, or exercisable or exchangeable for, such stock.
The exercise price of each option to acquire Common Stock (each, a
“Company Stock Option”) is no less than the fair market
value of a share of Common Stock as determined on the date of grant
of such Company Stock Option. All grants of Company Stock
Options were validly issued and properly approved by the Board of
Directors of the Company in material compliance with all applicable
laws and the terms of the plans under which such Company Stock
Options were issued and were recorded on the Company’s
financial statements in accordance with generally accepted
accounting principles, and no such grants involved any “back
dating”, “forward dating,” “spring
loading” or similar practices with respect to the effective
date of grant. The Common Stock and the Shares conform
in all material respects to all statements in relation thereto
contained in the Registration Statement and the Statutory
Prospectus and the Prospectus. All outstanding shares of
capital stock of each of the Company’s subsidiaries have been
duly authorized and validly issued, and are fully paid and
nonassessable and are owned directly by the Company or by another
wholly owned subsidiary of the Company free and clear of any
security interests, liens, encumbrances, equities or claims, other
than those described in the Statutory Prospectus and the
Prospectus.
(t)
No holder of any security of the
Company has any right, which has not been waived, to have any
security owned by such holder included in the Registration
Statement or to demand registration of any security owned by such
holder for a period of 90 days after the date of this
Agreement. Each director and executive officer of the Company
listed on Schedule II hereto has delivered to the
Representative his executed written lock-up agreement in the form
attached to this Agreement as Exhibit A hereto
(“Lock-Up Agreement”).
(u)
There are no legal or governmental
proceedings pending to which the Company or any of its subsidiaries
is a party or of which any property of the Company or any of its
subsidiaries is the subject which, if determined adversely to the
Company or any of its subsidiaries could individually or in the
aggregate have a Material Adverse Effect; and, to the knowledge of
the Company, no such proceedings are threatened or contemplated by
governmental authorities or threatened by others.
(v)
All necessary corporate action has
been duly and validly taken by the Company and to authorize the
execution, delivery and performance of this Agreement and the
issuance and sale of the Shares by the Company.
10
(w)
Neither the Company nor any of its
subsidiaries is involved in any labor dispute nor, to the knowledge
of the Company, is any such dispute threatened, which dispute would
have a Material Adverse Effect. The Company is not aware of
any existing or imminent labor disturbance by the employees of any
of its principal suppliers or contractors which would have a
Material Adverse Effect. The Company is not aware of any threatened
or pending litigation between the Company or its subsidiaries and
any of its executive officers which, if adversely determined, could
have a Material Adverse Effect.
(x)
No transaction has occurred between
or among the Company and any of its officers or directors,
shareholders or any affiliate or affiliates of any such officer or
director or shareholder that is required to be described in and is
not described in the Registration Statement, the Statutory
Prospectus and the Prospectus.
(y)
The Company has not taken, nor will
it take, directly or indirectly, any action designed to or which
might reasonably be expected to cause or result in, or which has
constituted or which might reasonably be expected to constitute,
the stabilization or manipulation of the price of the Common Stock
or any security of the Company to facilitate the sale or resale of
any of the Shares.
(z)
The Company and each of its
subsidiaries has filed all Federal, state, local and foreign tax
returns which are required to be filed through the date hereof,
which returns are true and correct in all material respects or has
received timely extensions thereof, and has paid all taxes shown on
such returns and all assessments received by it to the extent that
the same are material and have become due, except in each case
where such failure to file or pay would not have a Material Adverse
Effect. There are no tax audits or investigations pending, which if
adversely determined would have a Material Adverse Effect; nor are
there any material proposed additional tax assessments against the
Company or any of its subsidiaries.
(aa)
The Shares have been duly authorized
for listing on The NASDAQ Global Market of The NASDAQ Stock Market
LLC.
(bb)
The Company has taken no action
designed to, or likely to have the effect of, terminating the
registration of the Common Stock under the Exchange Act or the
listing of the Common Stock on The NASDAQ Global Market, nor has
the Company received any notification that the Commission or The
NASDAQ Global Market is contemplating terminating such registration
or listing.
(cc)
The books, records and accounts of
the Company and its subsidiaries accurately and fairly reflect in
all material respects, the transactions in, and dispositions of,
the assets of, and the results of operations of, the Company and
its subsidiaries. The Company and each of its subsidiaries
maintains a system of internal accounting controls sufficient to
provide reasonable assurances that (i) transactions are
executed in accordance with management’s general or specific
authorizations, (ii) transactions are recorded as necessary to
permit preparation of financial statements in accordance with
generally accepted accounting principles and to maintain asset
accountability, (iii) access to assets is permitted only in
accordance with management’s general or specific
authorization and (iv) the recorded accountability for assets
is compared with
11
the existing assets at reasonable intervals and
appropriate action is taken with respect to any
differences.
(dd)
The Company has established and
maintains disclosure controls and procedures (as such term is
defined in Rule 13a-15 under the Exchange Act), which:
(i) are designed to ensure that material information relating
to the Company is made known to the Company’s principal
executive officer and its principal financial officer by others
within the Company, particularly during the periods in which the
periodic reports required under the Exchange Act are required to be
prepared; (ii) provide for the periodic evaluation of the
effectiveness of such disclosure controls and procedures at the end
of the periods in which the periodic reports are required to be
prepared; and (iii) are effective in all material respects to
perform the functions for which they were established.
(ee)
Based on the evaluation of its
disclosure controls and procedures, the Company is not aware of
(i) any significant deficiency in the design or operation of
internal controls which could adversely affect the Company’s
ability to record, process, summarize and report financial data or
any material weaknesses in internal controls; or (ii) any
fraud, whether or not material, that involves management or other
employees who have a role in the Company’s internal
controls.
(ff)
Except as described in the Statutory
Prospectus and the Prospectus and as pre-approved in accordance
with the requirements set forth in Section 10A of the Exchange
Act, the Auditor has not been engaged by the Company to perform any
“prohibited activities” (as defined in Section 10A
of the Exchange Act).
(gg)
Except as described in the Statutory
Prospectus and the Prospectus, there are no material off-balance
sheet arrangements (as defined in Item 303 of Regulation S-K) that
have or are reasonably likely to have a material current or future
effect on the Company’s financial condition, revenues or
expenses, changes in financial condition, results of operations,
liquidity, capital expenditures or capital resources.
(hh)
The Company’s Board of
Directors has validly appointed an audit committee whose
composition satisfies the requirements of
Rule 5605(c)(2) of the Listing Rules of NASDAQ (the
“NASDAQ Rules”) and the Company’s Board of
Directors and/or the audit committee has adopted a charter that
satisfies the requirements of Rule 5605(c)(1) of the
NASDAQ Rules. The audit committee has reviewed the adequacy
of its charter within the past twelve months.
(ii)
There is and has been no failure on
the part of the Company or any of its directors or officers, in
their capacities as such, to comply with any applicable provision
of the Sarbanes-Oxley Act of 2002, including, without limitation,
Section 402 related to loans and Sections 302 and 906 related
to certifications.
(jj)
The Company and its subsidiaries are
insured by insurers of recognized financial responsibility against
such losses and risks and in such amounts as are customary for
companies in the Company’s industry and for companies of
comparable size, market capitalization and stage of business and
clinical development after giving effect to the transactions
described in the
12
Statutory Prospectus and the Prospectus; all
policies of insurance and fidelity or surety bonds insuring the
Company or any of its subsidiaries or the Company’s or its
subsidiaries’ respective businesses, assets, employees,
officers and directors are in full force and effect; the Company
and each of its subsidiaries are in compliance with the terms of
such policies and instruments in all material respects; and neither
the Company nor any subsidiary of the Company has any reason to
believe that it will not be able to renew its existing insurance
coverage as and when such coverage expires or to obtain similar
coverage from similar insurers as may be necessary to continue its
business at a cost that is not materially greater than the current
cost of such coverage. Neither the Company nor any of its
subsidiaries has been denied any insurance coverage which it has
sought or for which it has applied.
(kk)
Each approval, consent, order,
authorization, designation, declaration or filing of, by or with
any regulatory, administrative or other governmental body necessary
in connection with the execution and delivery by the Company of
this Agreement and the consummation of the transactions herein
contemplated required to be obtained or performed by the Company
(except such additional steps as may be required by the Financial
Industry Regulatory Authority (“FINRA”) or may be
necessary to qualify the Shares for public offering by the
Underwriters under the state securities or Blue Sky laws) has been
obtained or made and is in full force and effect.
(ll)
There are no affiliations with FINRA
among the Company’s officers, directors or, to the knowledge
of the Company, any five percent or greater stockholder of the
Company, except as set forth in the Registration Statement or
otherwise disclosed in writing to the Representative.
(mm)
As of the date hereof, the Company
satisfied and satisfies, respectively, the pre-1992 eligibility
requirements for the use of a registration statement on
Form S-3 in connection with the offering of the Shares
contemplated thereby (the pre-1992 eligibility requirements for the
use of the registration statement on Form S-3 include
(i) having a non-affiliate, public common equity float of at
least $150 million or a non-affiliate, public common equity float
of at least $100 million and annual trading volume of at least
three million shares and (ii) having been subject to the
Exchange Act reporting requirements for a period of 36
months).
(nn)
(i) Each of the Company and
each of its subsidiaries is in compliance in all material respects
with all rules, laws and regulation relating to the use, treatment,
storage and disposal of toxic substances and protection of health
or the environment which are applicable to its business
(“Environmental Law”); (ii) neither the Company
nor its subsidiaries has received any notice from any governmental
authority or third party of an asserted claim under Environmental
Laws; (iii) each of the Company and each of its subsidiaries
has received all permits, licenses or other approvals required of
it under applicable Environmental Laws to conduct its business and
is in compliance with all terms and conditions of any such permit,
license or approval; (iv) to the Company’s knowledge, no
facts currently exist that will require the Company or any of its
subsidiaries to make future material capital expenditures to comply
with Environmental Laws; and (v) no property which is or has
been owned, leased or occupied by the Company or its subsidiaries
has been designated as a Superfund site pursuant to the
Comprehensive Environmental Response, Compensation of Liability Act
of 1980, as amended (42 U.S.C. Section 9601, et. seq.)
(“CERCLA”), or otherwise designated as a contaminated
site
13
under applicable state or local law.
Neither the Company nor any of its subsidiaries has been named as a
“potentially responsible party” under the CERCLA
1980.
(oo)
In the ordinary course of its
business, the Company periodically reviews the effect of
Environmental Laws on the business, operations and properties of
the Company and its subsidiaries, in the course of which the
Company identifies and evaluates associated costs and liabilities
(including, without limitation, any capital or operating
expenditures required for clean-up, closure of properties or
compliance with Environmental Laws, or any permit, license or
approval, any related constraints on operating activities and any
potential liabilities to third parties). On the basis of such
review, the Company has reasonably concluded that such associated
costs and liabilities would not, singly or in the aggregate, have a
Material Adverse Effect.
(pp)
The Company is not and, after giving
effect to the offering and sale of the Shares and the application
of proceeds thereof as described in the Statutory Prospectus and
the Prospectus, will not be an “investment company”
within the meaning of the Investment Company Act of 1940, as
amended (the “Investment Company Act”).
(qq)
The Company or any other person
associated with or acting on behalf of the Company including,
without limitation, any director, officer, agent or employee of the
Company or its subsidiaries, has not, directly or indirectly, while
acting on behalf of the Company or its subsidiaries (i) used
any corporate funds for unlawful contributions, gifts,
entertainment or other unlawful expenses relating to political
activity; (ii) made any unlawful payment to foreign or
domestic government officials or employees or to foreign or
domestic political parties or campaigns from corporate funds;
(iii) violated any provision of the Foreign Corrupt Practices
Act of 1977, as amended; or (iv) made any other unlawful
payment.
(rr)
The operations of the Company and
its subsidiaries are in compliance in all material respects with
applicable financial recordkeeping and reporting require